References
- Baka E, Comer JE, Takács-Novák K. (2008). Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J Pharm Biomed Anal 46:335–41
- Birch AM, Buckett LK, Turnbull AV. (2010). DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Dev 13:489–96
- Bueters T, Dahlström J, Kvalvågnaes K, et al. (2011). High-throughput analysis of standardized pharmacokinetic studies in the rat using sample pooling and UPLC–MS/MS. J Pharm Biomed Anal 55:1120–6
- Cases S, Smith SJ, Zheng Y-W, et al. (1998). Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 95:13018–23
- Cases S, Stone SJ, Zhou P, et al. (2001). Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 276:38870–6
- Chen HC, Farese RV. (2005). Inhibition of triglyceride synthesis as a treatment strategy for obesity lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 25:482–6
- Cheng D, Iqbal J, Devenny J, et al. (2008). Acylation of Acylglycerols by Acyl Coenzyme A: Diacylglycerol Acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption. J Biol Chem 283:29802–11
- Dow RL, Andrews M, Aspnes GE, et al. (2011). Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino [2, 3-d] pyrimidine core. Bioorg Med Lett 21:6122–5
- Grès MC, Julian B, Bourriè M, et al. (1998). Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 15:726–33
- Hiramine Y, Tanabe T. (2011). Characterization of acyl-coenzyme A: diacylglycerol acyltransferase (DGAT) enzyme of human small intestine. J Physiol Biochem 67:259–64
- Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biomed Pharmacol 47:1469–79
- Kwak HJ, Pyun YM, Kim JY, et al. (2013). Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents. Bioorg Med Lett 23:4713–18
- Lipinski CA. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235–49
- Liu L, Zhang Y, Chen N, et al. (2007). Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest 117:1679–89
- Mahat B, Chae JW, Baek IH, et al. (2012). Physicochemical characterization and toxicity of decursin and their derivatives from Angelica gigas. Biol Pharm Bull 35:1084–90
- Oelkers P, Behari A, Cromley D, et al. (1998). Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes. J Biol Chem 273:26765–71
- Reasner CA. (2008). Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 52:136–44
- Serrano-Wu MH, Coppola GM, Gong Y, et al. (2012). Intestinally targeted diacylglycerol acyltransferase 1 (DGAT1) inhibitors robustly suppress postprandial triglycerides. ACS Med Chem Lett 3:411–5
- Smith SJ, Cases S, Jensen DR, et al. (2000). Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 25:87–90
- Song JS, Rho HJ, Park JS, et al. (2011). Preclinical pharmacokinetics of PDE-310, a novl PDE4 inhibitor. Drug Metab Pharmacokinetics 26:192–200
- Stone SJ, Myers HM, Watkins SM, et al. (2004). Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 279:11767–76
- Zalewski A, Macphee C. (2005). Role of lipoprotein-associated phospholipase A2 in atherosclerosis biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25:923–31